Acidic Cannabinoid Precursors Were Part of the Assay’s Specificity Question
The automated method considered whether acidic cannabinoid precursors could generate the neutral compounds being reported. This is a different identification question from whether an unrelated drug interferes with an assay.
The potential analytical pathway
THC-acid and related acidic cannabinoids can become different chemical species through decarboxylation. Frei and colleagues examined selectivity and specificity in a method that included derivatization before gas chromatography–tandem mass spectrometry. They reported no interfering signal in the challenged samples and interpreted the findings as supporting precursor stability under the method conditions.
The proposed explanation was qualified
The authors suggested that silylation protected the carboxylic-acid group and thereby prevented decarboxylation. That explanation should remain a proposed mechanism rather than a universal property of every heated cannabis assay. A different preparation, temperature sequence or derivatization protocol would require its own specificity evidence.
Why precursor evidence matters
A result should identify the compound the laboratory intended to measure and whether related precursors could contribute to that signal during processing. The absence of observed interference in these experiments supports this particular workflow; it does not establish all conceivable isomer and precursor challenges. This was analytical validation in blood and urine matrices, not a study showing that a measured neutral cannabinoid concentration proves impairment or the original composition of a consumed product.
Related analysis: the automated cannabinoid assay.
Research cited
Frei and colleagues (2022). Quantitative determination of five cannabinoids in blood and urine by gas chromatography tandem mass spectrometry applying automated on-line solid phase extraction. DOI: 10.1002/dta.3241.
